Company intelligence / Profile preview

Tara-ImmunoOncology

New York, New York, United States

Ownership: Private
Development stage: Other

Overview

TARA-002, an investigational cell therapy, showed 80% complete response rate at any time in BCG-unresponsive NMIBC (small cohort); 72.4% CR in BCG-naïve NMIBC with 69.2% at 6 months and 50% at 12 months; positive interim Phase 2 STARBORN-1 results in lymphatic malformations with 80-100% clinical success rates and favorable safety[2][3][4][6][7].

Therapeutic areas: OncologyRare Diseases
Modalities: Cell therapy
Industry: Biotech

Beyond the preview

Go deeper on Tara-ImmunoOncology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tara-ImmunoOncology.

Explore the full profile